Cells appearing normal may actually be harbingers of lung cancer
MD Anderson News Release March 07, 2014
Tissue analysis near tumors holds promise for earlier detection, new treatments
MD Anderson News Release 03/07/2014
Seemingly healthy cells may in fact hide clues that lung cancer will later develop, according to a study led by researchers at The University of Texas MD Anderson Cancer Center The research is published online in the Journal of the National Cancer Institute.
Examination of gene expression in patients with non-small cell lung cancer (NSCLC) showed the area adjacent to tumors is rich with cancer markers. In addition, researchers discovered the previously unknown role of a cancer-promoting gene in the airways of smokers with lung cancer.
“We believe this study has a “double whammy” application,” said study lead author Humam Kadara, Ph.D., assistant professor, Translational Molecular Pathology at MD Anderson. “These cancer-associated changes that distinguish the airways of smokers with lung cancer and healthy smokers may help us diagnose lung cancer earlier and develop more effective strategies for treatment.”
Field cancerization may yield answers
Lung cancer is the leading cause of cancer death in men and women in the United States. The American Cancer Society estimates more than 224,000 cases are diagnosed each year, and more than 159,000 people die of the disease. Almost 90 percent of lung cancers are NSCLC.
Symptoms of lung cancer usually don’t appear until the disease is advanced and untreatable. Although it’s believed to start as pre-cancerous changes in the lung, little is known about those changes that lead to lung cancer.
Field cancerization (FC) is a phenomenon in which large areas of cells are affected by a cancer-causing event, such as smoking. This is the first effort to comprehensively examine gene expression, known as the transcriptome, of the adjacent airway field cancerization in NSCLC.
Previous research, including pioneering work at MD Anderson by this study’s senior author Ignacio Wistuba, M.D., and others, has shown normal-appearing tissue close to lung premalignant and cancer lesions may have tumor-associated molecular abnormalities. And it’s known cigarette smoke induces widespread cellular changes and premalignant lesions in the lungs of smokers.
Potentially cancer-causing genes discovered
The study included 20 patients with stages I to III NSCLC, including five non-smokers and 15 smokers. Various genetic testing methods were used to examine lung tumors, uninvolved lung tissue and normal-appearing airways located varying distances from the tumors.
Researchers identified 1,661 differentially expressed gene features between tumors and airways compared with normal lung tissue. A subset of these changes was much more prevalent in lung-cancer patients than cancer-free smokers.
In addition, 422 genes, and key cancer-associated signaling pathways, were progressively expressed in airways, with a more intense presence closer to the tumor and tapering at further distances. This gradient site-dependent effect is consistent with NSCLC expression patterns.
Furthermore, higher levels of LAPTM4B, a gene that has been found in liver, lung, breast, ovarian and gastric cancers, were found in airways closer to tumors. It also aids in autophagy, a self-cannibalization mechanism that helps cells survive. LAPTM4B overexpression can cause resistance to certain types of chemotherapy.
“This is the first time the role of this gene in lung cancer has been studied,” Kadara said. “It was highly over-expressed in adjacent normal cells, indicating the possibility of future detection and treatment strategies.”
Larger studies of other lung cancer subtypes planned
The research group plans to move forward with more-advanced technology and larger populations to investigate field cancerization in other lung cancer subtypes, such as small-cell lung cancer, in smokers and in lung cancers that develop in non-smokers.
“We’re just beginning to understand the relevance of airway field cancerization to lung cancer detection and development of treatment and prevention strategies,” Kadara said.
Other MD Anderson researchers included Wistuba, who chairs Translational Molecular Pathology, holds the Anderson Clinical Faculty Chair for Cancer Treatment and Research and has an appointment in Thoracic/Head and Neck Medical Oncology; Junya Fujimoto, M.D., Ph.D., Yuho Maki, M.D. Ph.D., Melinda M. Garcia, Chi-Wan Chow, D.V.M., Zuoming Chu and Gabriella Mendoza, of Translational Molecular Pathology; Mohamed Kabbout, Ph.D., and Waun Ki Hong, M.D., of Thoracic/Head and Neck Medical Oncology; Neda Kalhor, M.D., and Cesar Moran, M.D., of Pathology; Suk-Young Yoo, Ph.D., Li Shen, Jing Wang, Ph.D., and Kevin Coombes, Ph.D., of Bioinformatics.
Also on the team were Adam Gower, Ph.D., and Avrum Spira, M.D., of Computational Medicine at Boston University.
This work was funded in part by grants from the Lung Cancer Research Foundation, the Jimmy Lane Hewlett Lung Cancer Research Fund, National Cancer Institute lung cancer SPORE grant (P50 CA70907), Department of Defense grants and MD Anderson’s NCI Cancer Center Support grant (CA16672).